Table 6.
Association between flavonol intake by serum IL-6 concentrations and colorectal adenoma recurrence among intervention group participants of the Polyp Prevention Trial (n=872)
| Flavonol* (in mg/d) | Interleukin-6† (in pg/mL) | Adenoma Recurrence (T4) |
||||||
|---|---|---|---|---|---|---|---|---|
| No | Advanced | High Risk | Any | |||||
| n (%) | n (%) | OR (95%CI)‡ | n (%) | OR (95%CI)‡ | n (%) | OR (95%CI)‡ | ||
| Mean (T1,2,3) | Baseline (T0) | |||||||
| Low | High > 1.90 | 131 (58.0) | 16 (7.1) | 1.00 | 38 (16.8) | 1.00 | 95 (42.0) | 1.00 |
| ≤29.6 | Low ≤ 1.90 | 131 (62.4) | 20 (9.5) | 1.57 (0.75–3.27) | 24 (11.4) | 0.81 (0.45–1.48) | 79 (37.6) | 0.94 (0.63–1.40) |
| High | High > 1.90 | 128 (61.2) | 6 (2.9) | 0.42 (0.15–1.15) | 15 (7.2) | 0.47 (0.24–0.93) | 81 (38.8) | 0.97 (0.65–1.45) |
| >29.6 | Low ≤ 1.90 | 134 (59.0) | 7 (3.1) | 0.68 (0.25–1.86) | 23 (10.1) | 0.99 (0.52–1.89) | 93 (41.0) | 1.30 (0.87–1.95) |
| Mean (T1,2,3) | Trial (T1,3) | |||||||
| Low | High > 1.99 | 144 (58.5) | 20 (8.1) | 1.00 | 43 (17.5) | 1.00 | 102 (41.5) | 1.00 |
| ≤29.6 | Low ≤ 1.99 | 118 (62.1) | 16 (8.4) | 1.22 (0.58–2.54) | 19 (10.0) | 0.65 (0.35–1.20) | 72 (37.9) | 0.99 (0.58–1.47) |
| High | High > 1.99 | 108 (57.1) | 7 (3.7) | 0.51 (0.20–1.31) | 18 (9.5) | 0.64 (0.33–1.23) | 81 (42.9) | 1.19 (0.80–1.79) |
| >29.6 | Low ≤ 1.99 | 154 (62.3) | 6 (2.4) | 0.40 (0.15–1.07) | 20 (8.1) | 0.64 (0.34–1.19) | 93 (37.7) | 1.11 (0.75–1.64) |
| Mean (T1,2,3) C | Change (T1,3–T0) | |||||||
| Low | High > 0.06 | 138 (58.2) | 22 (9.3) | 1.00 | 36 (15.2) | 1.00 | 99 (41.8) | 1.00 |
| ≤29.6 | Low ≤ 0.06 | 124 (62.3) | 14 (7.0) | 0.72 (0.35–1.51) | 26 (13.1) | 0.78 (0.43–1.40) | 75 (37.7) | 0.86 (0.58–1.27) |
| High | High > 0.06 | 114 (57.6) | 9 (4.6) | 0.62 (0.26–1.49) | 21 (10.6) | 0.90 (0.47–1.72) | 84 (42.4) | 1.20 (0.80–1.80) |
| >29.6 | Low ≤ 0.06 | 148 (62.2) | 4 (1.7) | 0.19 (0.06–0.58) | 17 (7.1) | 0.51 (0.27–0.99) | 90 (37.8) | 0.98 (0.67–1.45) |
*
Flavonol intake below or above the median of the mean intake during the first 3 trial years (T1,2,3).
†
Interleukin-6 concentrations below or above the median baseline IL-6 concentration (T0), of the median trial IL-6 concentration (T1,3) and of the median change in IL-6 concentrations from baseline [Change (T 1,3–T0)].
‡
Multivariate OR and 95% CI models were adjusted for age tertiles (<58, 58–66, >66 yrs), sex, average BMI (<25, 25.0–29.9, ≥30 kg/m2), current smoking status, and average energy intake (continuous) during the first 3 trial years.